Bayer reaches settlement to resolve Xarelto™ litigation
- Details
- Category: Bayer
More than five years after the Xarelto™ litigation began, and with Bayer and Janssen Pharmaceuticals prevailing in all six cases that went to trial, the companies have reached an agreement in principle to settle in the amount of 775 million U.S. dollars.
Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics
- Details
- Category: Pfizer
PARIS & Vivet Therapeutics ("Vivet"), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares.
Bayer is taking collaboration with health care start-ups to the next level
- Details
- Category: Bayer
As a pioneer when it comes to collaborating with digital health start-ups, Bayer is now taking the next step. Instead of one-off startup programs, it is now focusing on collaborating in specific digital health focus areas, e.g. digital therapeutics, AI for drug discovery, and patient engagement platforms to name a few. To do this, Bayer is combining the G4A programs and concentrating on longer-term collaborations and investments.
FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Merck to collaborate with GenScript to accelerate cell and gene therapy industrialization in China
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced the signing of a non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing.
US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis
- Details
- Category: AstraZeneca
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for saracatinib, a potential new medicine for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung disease that results in scarring (fibrosis) of the lungs. Saracatinib is an inhibitor of src kinase which regulates broad cell functions including cell growth and cell differentiation.
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
- Details
- Category: Novartis
At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis announced that it is joining the Coalition as a member contributor. In addition, the company announced its commitment to launch a multinational, prospective, randomized study with heart failure drug, Entresto® (sacubitril / valsartan), in people with chronic Chagas cardiomyopathy, one form of heart failure with reduced ejection fraction.
More Pharma News ...
- Merck announces collaboration with Iktos for generative artificial intelligence (AI) technology
- Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW
- Impact pioneers honored for groundbreaking ideas in the fields of healthcare and nutrition
- Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors
- Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
- Bayer Thrombosis Research Award 2019 goes to Dr. Changjun Yin
- Jury upholds Amgen's patents on Repatha® (evolocumab)